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Although the concept of probiotics is not new, the advent of
commercial products has refocused attention on their potential
uses and applications.1 Probiotics are defined as ‘live microbial
supplements, which when given in sufficient amounts, offer
health benefits beyond basic nutrition’. The organisms are
lactic acid bacteria (LAB), usually Lactobacilli and Bifidobacteria
species present as normal flora in healthy gastrointestinal
tracts. Because of their fastidious growth requirements, a
limited number of commercial products are available to the
public and health care professionals in South Africa. However,
in the last 2 years 5 new probiotic products have been
introduced onto the market, with the inevitable competition for
the consumers’ disposable income. Additionally, the products
have been introduced to health care professionals with a
variety of therapeutic claims for health and benefit, often with
extrapolated clinical evidence of efficacy.
Until recently, registration of these products was the domain
of the Department of Health and they were registered as food
supplements and designated as ‘generally regarded as safe’
(GRAS). Because therapeutic benefit is now substantiated with
published clinical trials, this regulatory function has shifted to
the Complementary Medicines Committee (CMC), set up by
the Medicines Control Council (MCC) as the appropriate body
to regulate these products.
Unfortunately, assessment of these products is limited by
the lack of independent technical expertise available in South
Africa and the expense of setting up the infrastructure to do
such testing. Therefore, products are currently not subjected to
stringent scrutiny; the manufacturers’ claims are difficult to
validate and the regulatory body has no mechanism to do post-
marketing surveillance. Standardising such evaluation with a
validated method would provide a means to assess and
compare products, confirm their contents and monitor the
effect of storage on their shelf life.
In a recent European survey of commercially available
probiotic products, the information on the labels did not
correlate with the results of the assessment.2 The same was true
in a survey of probiotic veterinary and human products
available in the USA.3 In a local assessment of commercial
yoghurts in South Africa, the results correlated poorly with the
label claims.4 Prompted by the European study by Temmerman
et al.2 and the USA study by Weese,3 we undertook an
evaluation of 9 probiotic products commercially available in
South Africa. Our aim was to determine if the label information
was respresentative of the actual contents of the product.
Purchase and shipping procedure
An independent retail pharmacist ordered a selection of
probiotic products via his usual wholesale suppliers. As there
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Background and objective. Although probiotics are not new, 5
new commercially available products have been launched
onto the South African market in the last 2 years. Evaluations
of products in the USA and Europe have shown poor
correlation between label claims and actual contents. We
undertook an evaluation of 9 products currently available on
the shelves in South Africa.
Methods and analysis. An independent laboratory was used. A
culture method involving serial dilutions on selective media
was used to obtain a colony count per gram for the indicated
organisms. A non-culture method, denaturing gradient gel
electrophoresis (DGGE), was used to determine the organisms
present in the products.
Results. Disturbingly, we found a relatively poor correlation
between the advertised and determined bacterial content.
Only 3 of the 9 products tested contained the bacteria
indicated on the label and 5 products contained sufficient
bacteria for a probiotic effect. The Enterococcus faecium, a
potential pathogen and Saccharomyces cerevisiae found in 2 of
the products are of concern.
Conclusion. This evaluation confirms that the contents of
several probiotics available in South Africa do not correspond
to the label claims. This is of concern as clinical efficacy is
dependent on strain specificity and organism numbers.
Current regulatory requirements do not address this
discrepancy. As such, we recommend that commercially
available probiotic products be screened annually, and the
results of such quality control measures be made available to
the Medicines Control Council (MCC).
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was no way to predict the batch, this was a random selection.
The products were kept refrigerated at 4°C until collected by
the courier. They were sent under cold chain conditions to the
Department of Microbiology at the University of Ghent in
Ghent, Belgium. Receipt of products in good condition was
acknowledged by e-mail. The Department of Microbiology at
Ghent University was chosen as it has done similar analysis
before and has no vested interest in any product.
Methods of analysis
Enumeration of the bacteria was performed on a culture-
dependent basis. Three selective culture media were used,
namely MRS (de Man Regosa and Sharpe) agar, M17 agar and
Modified Columbia agar to isolate lactobacilli, streptococci and
bifidobacteria respectively. One hundred microlitres of a ten-
fold dilution series of each product were plated in triplicate
onto the media. Plates were incubated aerobically for 24 hours
and under anaerobic and microaerophilic conditions for 72
hours. After incubation, the visible colonies were counted and
expressed as colony-forming units per gram (CFU/g),
representing the number of viable bacteria present in each
product.5
Identification of the bacteria present in the products was
performed on a culture-independent basis, using the
denaturing gradient gel electrophoresis (DGGE) technique.5 As
this validated method does not require culture it can be used
for a variety of product types and can differentiate between the
organisms when more than 1 is present in a product. The
technique involves the extraction of  bacterial DNA directly
from the product, amplification of certain DNA fragments and
separation by electrophoresis of these fragments through a
polyacrylamide gel. After digital capturing of the DNA-band
patterns, bacterial identification is achieved by comparing each
DNA band pattern against a DNA pattern database of reference
strains of organisms kept at the University of Ghent.
Results
As mentioned, previous studies have found a poor correlation
between label and product.2-4 Our evaluation of the products
available on the South African market shows a similar trend,
with only 3 of the 9 products containing the bacteria indicated
on the labels and only 5 products with sufficient bacteria for a
probiotic effect. The results are shown in Tables I and II.
In Table I, 3 products contained the bacteria indicated on
the label. These were the 2 BioPro Reuteri products, the
drinking straws and tablets containing Lactobacillus reuteri,
Infantiforte which contains Bifidobacterium infantis.
According to the label, Combiforte is a mixture of three
bacteria, Lactobacillus acidophilus, Bifidobacterium bifidus and 
B. longum. Our evaluation showed that only 2 bacterial species
are present and only the L. acidophilus corresponds to the label.
Table I. Results of the culture-independent analyses of 9 South African probiotic products in August 2003
Product Expiry date Organism on label Detected using DGGE Conclusion
BioPro Reuteri straws Aug 04 Lactobacillus reuteri Lactobacillus reuteri Product = label
BioPro Reuteri tablets Sep 04 Lactobacillus reuteri Lactobacillus reuteri Product = label
Combiforte capsules Mar 05 Lactobacillus acidophilus Lactobacillus acidophilus Partial correlation
Bifidobacterium bifidus Bifidobacterium infantis of label and product
Bifidobacterium longum
Culturelle sachets Jun 04 Bifidobacterium longum Bifidobacterium lactis Mislabelling
Lactobacillus acidophilus Lactobacillus paracasei Poor identification
Streptococcus thermophilus Enterococcus faecium
Culturelle tablets Jun 06 Bifidobacterium longum Bifidobacterium lactis Poor correlation
Lactobacillus rhamnosus Lactobacillus paracasei of product and 
label
Infantiforte capsules Jun 04 Bifidobacterium infantis Bifidobacterium infantis Product = label
Lacteol Forte capsules Jan 06 Lactobacillus acidophilus DNA from heat-killed Not measurable
bacteria not detectable
Lacteol Forte sachets Feb 05 Lactobacillus acidophilus DNA from heat-killed Not measurable
bacteria not detectable
Lactovita capsules Aug 04 Lactic acid bacillus Saccharomyces cerevisiae No bacteria
present
DGGE = denaturing gradient gel electrophoresis.
ORIGINAL ARTICLES
The  Bifidobacterium species present was identified as B. infantis
and those indicated on the label were not detected. There was
therefore partial correlation of  the label and the detected
contents of the product.
The two Culturelle products showed no correlation between
the label claim and the actual Lactobacillus and Bifidobacterium
species identified. In addition, the Streptococcus thermophilus
indicated on the label of the sachets was not detected. Instead,
we detected Enterococcus faecium, a potential pathogen
associated with invasive disease. In the report of the Joint Food
and Agricultural Organisation/World Health Organisation
(FAO/WHO) expert group issued in 2001,6 it was
recommended that enterococci should not be used as probiotics
as they can display or acquire resistance to vancomycin7 and
are commonly associated with nosocomial infections in
hospitals.
The label for Lactovita indicates that a lactic acid bacillus is
present, but it does not provide any detail of the species. The
product was found to contain only the yeast Saccharomyces
cerevisiae and no bacteria. Rare cases of vulvovaginitis have
been associated8 with this organism but it has low pathogenic
potential. Furthermore, the probiotic property of S. cerevisiae is
not established. The discrepancy between label and contents is
of concern.
The package inserts of the Lacteol Forte products indicate
the contents as killed bacteria. The destruction of the viable
bacteria involves exposing the organisms to a high temperature
sterilising process. During this process, proteins and DNA are
also denatured. This product therefore does not meet the
definition of a probiotic, as it contains no viable bacteria and
the sterilising process probably negates any potential effects of
secreted peptides such as bacteriocins with antibacterial
properties. Therefore, this product should not be registered as a
probiotic.
Table II indicates the results of the viable bacterial colony
counts. The expiry dates as indicated on the labels are included
in the table. As none were due to expire in 2003, viable
organisms should have been present. Of the 9 products tested,
only 5 contained sufficient numbers of organisms to have
probiotic potential.
In summary, according to our evaluation, only 3 products
meet the criteria of a probiotic as they contain: (i) the
organisms indicated on the label (Table I); and (ii) a sufficient
number of organisms for a clinical effect (Table II).
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Table II. Colony counts of viable bacteria in 9 South African probiotic products in August 2003 expressed as colony-forming
units (CFU) per gram
Lactobacilli and
other organism Bifidobacteria
Product Expiry date Detected on DGGE count (CFU/g) count (CFU/g) Conclusion
BioPro Reuteri Aug-04 Lactobacillus reuteri 8.32 x 107 0 Sufficient live
straws CFU/straw bacteria
BioPro Reuteri Sep-04 Lactobacillus reuteri 1.51 x 108 0 Sufficient live
chew tabs bacteria
Combiforte Mar-05 Lactobacillus 3.62 x 107 5.12 x 107 Sufficient live
capsules acidophilus bacteria
Bifidobacterium infantis
Culturelle June-04 Bifidobacterium lactis 1.05 x 105 1.16 x 107 Sufficient live
sachets Lactobacillus paracasei bacteria
Enterococcus faecium
Culturelle June-05 Bifidobacterium lactis 0 0 No living
tablets Lactobacillus paracasei bacteria present
Infantiforte Jun-04 Bifidobacterium infantis 0 4.34 x 107 Sufficient live
capsules bacteria
Lacteol Forte Jan-06 N/A 0 0 No living
capsules bacteria present
Lacteol Forte Feb-05 N/A 0 0 No living
sachets bacteria present
Lactovita Aug-04 Saccharomyces 0 0 No living
capsules cerevisiae bacteria present
DGGE = denaturing gradient gel electrophoresis.
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Discussion
The clinical uses of probiotics and their potential benefits have
recently been comprehensively reviewed by Mare and du Toit.1
These include stimulation of the immune system,
anticarcinogenic properties, cholesterol reduction, management
of lactose intolerance, alleviation of constipation, management
of infectious diarrhoea, management of peptic ulcer disease,
management of inflammatory bowel disease and the treatment
and prevention of urogenital infections.
The benefits show not only species-specific but also strain-
specific effects and therefore cannot be generalised to all the
LAB organisms. Due caution is therefore advised when
assessing the claims of benefit. Where possible, claims of
benefit of a particular product should be substantiated by the
results of well-designed clinical trials. Unfortunately, many of
the organisms in the products available in South Africa have
not been substantiated in peer-reviewed publications. Rather,
their claimed efficacies have been extrapolated from studies on
other similar organisms. The notable exception involves
Lactobacillus reuteri ATCC 55730 where the product available
corresponds to the organism for which the clinical data are
available. Although there are clinical data for Bifidobacteria
infantis registered with Nestlé in a milk product,9 extrapolation
of these data can be made to the Infantiforte B. infantis.
Although probiotics have GRAS registration, a few serious
infections (but to date no deaths) have been reported as being
directly attributable to probiotics. Therefore, finding E. faecium,
a known potential pathogen isolated from immune-
compromised patients is of concern as its presence is contrary
to international guidelines. The potential for antimicrobial
resistance is a further contraindication to its use in probiotic
products. In the interests of safety, products containing this
organism should be withdrawn.
The results of our evaluation clearly show the limitations of
the current system for the evaluation of probiotics for
registration and the lack of post-marketing surveillance. For
probiotics to be effective, they must meet the minimum
requirements of containing clinically validated species present
in sufficient and viable quantities. It would be interesting to
subject other new milk-based products such as yogurts and
infant milk formulas containing probiotics to the same quality
testing methods.
Conclusion
It is therefore in the interests of all that an evaluation system be
implemented to protect the consumer. The evaluation should
include a means of verifying label claims and assessment of the
effects of storage on the products. We believe that  our
evaluation partly addresses the problem and that the DGGE
method provides a suitable standard for organism
identification together with standardised quantification.
Furthermore, it is suggested that an independent laboratory
be used to do an annual random ‘off the shelf’ quality control
of the commercially available products. It is also suggested that
validated clinical data be the basis for registration of a
probiotic at the Complementary Medicines Committee (CMC)
of the Medicines Control Council (MCC).
Finally, the practice of substitution at pharmacy level should
be viewed with scepticism. Certain health benefits of probiotics
are strain specific. Strain definition of products should be
linked to efficacy, eliminating the current extrapolation of data
by some manufacturers. This together with questionable
quality threatens credibility of all probiotic products because
they cannot deliver the expected results.
E Elliott has received sponsorship from Nestlé and BioPro
Pharmaceuticals to present at congresses.
K Teversham is the medical advisor to Thebe Pharmaceuticals
who market BioPro Reuteri and who initiated this study.
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